Science & Innovation

Pipeline

Dorzagliatin

mGluR5

Poster and Presentation

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information

Corporate Communications

Portfolio Advisory Board

Senior Scientific Advisory Board

Media

Media Releases

Oct 12

2021

Hua's diabetes therapy may be first to show clinical remission

Aug 24

2020

Hua teams up with Bayer for dorzagliatin as diabetes treatment in China

Aug 13

2020

China Healthcare Report 2020

Sep 18

2018

Hua’s Institutional Advantage

Jun 18

2018

Hua Medicine-on call to fight diabetes in China

May 08

2018

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

Jan 30

2018

Braced for the Biotech Boom

Jan 12

2018

China’s Hua Medicine seeks funding for US$200m diabetes drug development plan

Nov 08

2017

New Business in Action | Ep.2 New Drugs: Harvest Time is Coming

About Us

Company Overview

Company History

Leadership Team

Portfolio Advisory Board

Senior Scientific Advisory Board

Partner

Media center

Research & Development

Inovation

Pipeline

Dorzagliatin

mGluR5

Company Publications

Peer Reviewed Publications

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Media

Company News

Media Releases

Video

Careers

Culture

Join Us

Product

HuaTangNing(華堂寧?)

Focus Us

Copyright ? 2024 Hua Medicine (Shanghai) Co., Ltd. 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號: （滬）-非經(jīng)營-2022-0079
滬ICP備14036654號-1

滬公網(wǎng)安備 31011502013809號 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.